Unlocking a $14B+ Market Opportunity

InnerView® is revolutionizing the $14B+ dental diagnostics market by addressing the industry’s #1 unmet need — detecting cracks and failing restorations.

With over 800M+ potential annual procedures and 1.4M dentists worldwide, the demand for advanced, scalable diagnostics has never been greater.

The Current Landscape

The Challenge

Despite advancements in dental technology, providers still rely on outdated methods to assess dental health.

The Growth
Potential

InnerView’s Competitive Advantage

Why InnerView Will Dominate

First-Mover Advantage

The only AI-powered diagnostic system addressing cracks and failing restorations.

FDA-Cleared Technology

FDA approval for crack detection is forecasted for Q3 2025.

Global Scalability

Universal compatibility and portability make InnerView adaptable to practices worldwide.

Recurring Revenue Model

Hardware sales, SaaS subscriptions, and disposable components drive sustainable, predictable growth.

The Growth Potential

Massive Global Opportunity

Projected Financial Growth

Strategic Rollout Plan

1

U.S. Expansion

Targeting 400,000+ U.S. dental professionals — expanding adoption to key specialties such as prosthodontics, endodontics, and periodontics.

2

Global Growth

FDA clearance for crack detection will expand use to natural teeth. Global rollout targets 1.44 million dentists across Europe, Asia, and South America.

3

AI-Driven Analysis

InnerView will leverage sinusoidal decomposition analysis to uncover cyclical patterns and subtle diagnostic trends, enabling predictive insights across patient populations and integrating advanced analytics into routine checkups.

Why Now?

Cracks and structural breakdowns are the #1 unmet diagnostic need in dentistry — estimated to be 3–4x more prevalent than what X-rays can reveal. 

While current diagnostics primarily focus on decay and bone-related issues, they can’t consistently detect these hidden structural failures or track their progression over time.

InnerView fills this critical gap, providing real-time, AI-driven data that gives clinicians clarity they’ve never had before.

This website contains information about prospective technologies currently under development and clinical evaluation. Certain diagnostic claims, such as AI/ML crack detection, refer to investigational devices that have not yet received FDA clearance.